Aytu BioPharma, Inc.AYTU

$2.31+0.20 (+9.48%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$24M
Micro-cap
+150%
2016 — today
10-Year Price
-100%
2016 — today
52-Week Range
$1.71$2.90
Current $2.31· 50%

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Valuation in context

P/E ratio
-0.5
N/A
Not meaningful — company is unprofitable
P/B ratio
0.7
Around average
Around the 10-year average
FCF Yield
6.8%
Near historic high
Near historic highs — last 10 years
Free · No credit card needed

Get alerted when AYTU is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.